Profile data is unavailable for this security.
About the company
Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.
- Revenue in EUR (TTM)196.34m
- Net income in EUR49.36m
- Incorporated1986
- Employees515.00
- LocationPharma Mar SAAvda. De los Reyes, 1, Pol. Ind. La MinaCOLMENAR VIEJO 28770SpainESP
- Phone+34 918466000
- Fax+34 918466001
- Websitehttps://www.pharmamar.com/es/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calliditas Therapeutics AB | 71.24m | -36.58m | 648.15m | 169.00 | -- | 8.59 | -- | 9.10 | -7.81 | -7.81 | 15.14 | 14.28 | 0.4705 | 6.70 | 16.05 | -- | -24.16 | -27.85 | -27.93 | -30.95 | 98.11 | -- | -51.35 | -125.04 | 4.33 | -- | 0.4875 | -- | 250.07 | -- | 17.59 | -- | -- | -- |
| Valneva SE | 361.30m | -143.28m | 650.92m | 700.00 | -- | 2.96 | -- | 1.80 | -1.24 | -1.24 | 3.30 | 1.59 | 0.5023 | 4.08 | 10.64 | -- | -19.92 | -12.90 | -36.17 | -20.26 | 10.20 | 38.81 | -39.66 | -26.40 | 1.40 | -3.62 | 0.4094 | -- | 3.80 | 27.97 | -95.14 | -- | 48.66 | -- |
| Basilea Pharmaceutica AG | 148.32m | 12.19m | 653.98m | 141.00 | 48.85 | -- | 49.18 | 4.41 | 1.02 | 1.02 | 12.46 | -1.73 | 0.6313 | 1.05 | 2.29 | 1,047,979.00 | 5.19 | -4.99 | 11.10 | -7.68 | 83.35 | 83.79 | 8.22 | -9.15 | 2.02 | 1.95 | 1.14 | -- | -0.241 | 7.80 | 277.82 | -- | 28.44 | -- |
| Boiron SA | 522.03m | 50.59m | 698.31m | 2.79k | 13.76 | 1.30 | 11.95 | 1.34 | 2.89 | 2.89 | 29.90 | 30.67 | 0.6938 | 1.71 | 7.11 | 188,527.30 | 6.71 | 5.96 | 8.45 | 7.50 | 70.06 | 76.84 | 9.67 | 8.41 | 2.28 | -- | 0.0453 | 46.86 | -11.37 | -5.82 | 8.95 | -18.15 | -10.06 | -9.90 |
| Puretech Health PLC | 17.14m | -12.46m | 700.30m | 95.00 | -- | 1.35 | -- | 40.87 | -0.038 | -0.038 | 0.0525 | 1.64 | 0.0216 | -- | 4.76 | 158,882.00 | -1.00 | 4.86 | -1.26 | 6.24 | -- | -- | -46.43 | 260.53 | -- | -- | 0.0771 | 0.00 | 47.76 | 31.45 | -1,111.83 | -- | 9.02 | -- |
| Surgical Science Sweden AB | 71.21m | 16.68m | 720.78m | 233.00 | 43.31 | 1.92 | 33.91 | 10.12 | 3.69 | 3.69 | 15.76 | 83.39 | 0.186 | 2.19 | 5.59 | -- | 4.36 | 4.04 | 4.65 | 4.32 | 66.23 | 70.67 | 23.42 | 20.67 | 2.26 | -- | 0.0247 | 0.00 | 118.81 | 69.51 | 117.95 | -- | 32.87 | -- |
| Gen Ilac ve Saglik Urunleri Sanayi ve | 262.35m | 52.06m | 729.91m | 542.00 | 14.02 | 5.42 | 13.21 | 2.78 | 3.60 | 3.60 | 18.16 | 9.31 | 1.88 | 8.29 | 17.11 | -- | 37.52 | -- | 50.51 | -- | 20.95 | -- | 19.99 | -- | 2.24 | -- | 0.101 | -- | 117.69 | -- | 247.58 | -- | -- | -- |
| Pharma Mar SA | 196.34m | 49.36m | 812.20m | 515.00 | 16.21 | 3.59 | 14.70 | 4.14 | 2.73 | 2.73 | 10.87 | 12.31 | 0.5156 | 0.7126 | 4.89 | 381,248.50 | 12.96 | 19.91 | 17.08 | 28.87 | 93.05 | 93.94 | 25.14 | 28.43 | 2.54 | 68.89 | 0.1605 | -- | -14.57 | 4.33 | -46.85 | -- | 13.67 | -- |
| BioGaia AB | 97.96m | 33.17m | 813.63m | 212.00 | 25.47 | 4.83 | 23.06 | 8.31 | 3.70 | 3.70 | 10.93 | 19.53 | 0.5085 | 2.46 | 8.86 | 5,207,345.00 | 17.22 | 17.02 | 18.46 | 18.91 | 72.64 | 73.60 | 33.86 | 27.77 | 10.03 | -- | 0.0056 | 74.20 | 40.61 | 12.41 | 90.44 | 15.66 | -7.62 | 10.01 |
| Pharming Group N.V. | 189.63m | 12.61m | 824.37m | 321.00 | 78.22 | 4.37 | 33.28 | 4.35 | 0.0161 | 0.0161 | 0.2721 | 0.2875 | 0.4996 | 0.5044 | 7.14 | -- | 3.32 | 8.43 | 3.82 | 11.16 | 91.46 | 88.36 | 6.65 | 14.24 | 3.94 | 1.67 | 0.4489 | -- | 3.39 | 15.26 | -14.52 | -- | -11.60 | -- |
| EIS Eczcb Ilc Sn ve Fn Ytm Sny ve Tct AS | 88.20m | 201.28m | 931.69m | 1.16k | 4.63 | 1.03 | 4.55 | 10.56 | 6.10 | 6.10 | 2.67 | 27.36 | 0.1099 | 2.58 | 5.56 | 1,582,207.00 | 25.07 | 15.36 | 26.55 | 16.30 | 36.27 | 34.58 | 228.23 | 113.93 | 1.42 | -- | 0.0945 | -- | 65.89 | 25.08 | 230.63 | 97.42 | 82.99 | -- |
| Euroapi SAS | 943.90m | 2.00m | 947.86m | 3.34k | 632.49 | 0.8478 | 11.76 | 1.00 | 0.0159 | 0.0159 | 10.30 | 11.83 | -- | -- | -- | -- | -- | -- | -- | -- | 16.44 | -- | 0.2225 | -- | 1.05 | 11.33 | 0.0363 | -- | 9.87 | -- | 5.06 | -- | -- | -- |
| AddLife AB | 806.04m | 42.59m | 957.75m | 2.20k | 23.24 | 2.25 | 8.96 | 1.19 | 3.94 | 3.94 | 74.59 | 40.78 | 0.7681 | 3.99 | 6.57 | -- | 4.08 | 7.08 | 6.77 | 12.61 | 37.73 | 36.34 | 5.32 | 7.05 | 0.4322 | 3.94 | 0.5294 | 32.50 | 13.66 | 31.24 | -33.20 | 31.88 | 44.26 | 18.05 |
| FAES Farma SA | 438.75m | 89.55m | 972.75m | 1.77k | 10.65 | 1.59 | 8.94 | 2.22 | 0.2938 | 0.2938 | 1.44 | 1.96 | 0.6402 | 1.41 | 3.87 | 248,445.10 | 13.06 | 13.04 | 14.99 | 15.38 | 64.25 | 63.49 | 20.40 | 19.02 | 2.10 | -- | 0.0515 | -- | 10.09 | 9.83 | 8.69 | 16.70 | 37.20 | -- |
| Cosmo Pharmaceuticals NV | 102.05m | 17.22m | 976.18m | 295.00 | 53.05 | 1.98 | 31.14 | 9.57 | 1.04 | 1.04 | 6.19 | 27.98 | 0.1305 | 3.29 | 3.24 | 344,619.80 | 2.24 | -0.3478 | 2.62 | -0.3699 | 60.34 | 58.40 | 17.15 | -3.16 | 1.51 | 8.08 | 0.2724 | -- | 56.88 | 8.71 | -20.52 | -- | -19.80 | -- |
| Vetoquinol SA | 536.71m | 48.07m | 1.01bn | 2.55k | 20.82 | 2.16 | 12.27 | 1.87 | 4.06 | 4.06 | 45.36 | 39.24 | 0.875 | 2.34 | 5.43 | 210,803.20 | 7.82 | 6.97 | 10.28 | 9.18 | 49.25 | 61.10 | 8.94 | 8.78 | 1.15 | 1,370.76 | 0.0408 | 15.15 | 21.94 | 8.27 | 227.04 | 17.70 | 18.97 | 13.22 |
Data as of Mar 30 2023. Currency figures normalised to Pharma Mar SA's reporting currency: Euro EUR
7.45%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 03 Mar 2023 | 381.44k | 2.06% |
| Norges Bank Investment Managementas of 31 Dec 2022 | 261.81k | 1.41% |
| BlackRock Fund Advisorsas of 01 Mar 2023 | 204.66k | 1.10% |
| Santander Asset Management SA SGIICas of 30 Sep 2022 | 109.54k | 0.59% |
| Dimensional Fund Advisors LPas of 02 Mar 2023 | 107.04k | 0.58% |
| BlackRock Advisors (UK) Ltd.as of 01 Mar 2023 | 71.71k | 0.39% |
| Jupiter Asset Management Ltd.as of 30 Nov 2022 | 63.91k | 0.34% |
| Credit Suisse AGas of 31 Jan 2023 | 62.62k | 0.34% |
| TIAA-CREF Investment Management LLCas of 31 Jan 2023 | 61.60k | 0.33% |
| Teachers Advisors LLCas of 31 Jan 2023 | 57.44k | 0.31% |
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
